1 Citation (Scopus)

Abstract

The discipline of neurotheranostics was forged to improve diagnostic and therapeutic clinical outcomes for neurological disorders. Research was facilitated, in largest measure, by the creation of pharmacologically effective multimodal pharmaceutical formulations. Deployment of neurotheranostic agents could revolutionize staging and improve nervous system disease therapeutic outcomes. However, obstacles in formulation design, drug loading and payload delivery still remain. These will certainly be aided by multidisciplinary basic research and clinical teams with pharmacology, nanotechnology, neuroscience and pharmaceutic expertise. When successful the end results will provide “optimal” therapeutic delivery platforms. The current report reviews an extensive body of knowledge of the natural history, epidemiology, pathogenesis and therapeutics of neurologic disease with an eye on how, when and under what circumstances neurotheranostics will soon be used as personalized medicines for a broad range of neurodegenerative, neuroinflammatory and neuroinfectious diseases.

Original languageEnglish (US)
JournalAdvanced Drug Delivery Reviews
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Precision Medicine
Nervous System Diseases
Drug Compounding
Nanotechnology
Drug Design
Therapeutics
Neurosciences
Natural History
Research
Epidemiology
Pharmacology
Pharmaceutical Preparations

Keywords

  • Alzheimer's disease (AD)
  • Blood brain barrier (BBB)
  • Brain-targeted nanoparticles
  • Magnetic resonance imaging (MRI)
  • Nanomedicine
  • Neurodegenerative disorders
  • Neuroimaging
  • Neurotheranostics
  • Parkinson's disease (PD)
  • Single photon emission computed tomography (SPECT/CT)
  • Theranostics

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Neurotheranostics as personalized medicines. / Kevadiya, Bhavesh D.; Ottemann, Brendan M.; Thomas, Midhun Ben; Mukadam, Insiya; Nigam, Saumya; McMillan, JoEllyn M; Gorantla, Santhi; Bronich, Tatiana K; Edagwa, Benson J; Gendelman, Howard Eliot.

In: Advanced Drug Delivery Reviews, 01.01.2018.

Research output: Contribution to journalArticle

@article{5fb416c984414887b2e5dd593fb3ee03,
title = "Neurotheranostics as personalized medicines",
abstract = "The discipline of neurotheranostics was forged to improve diagnostic and therapeutic clinical outcomes for neurological disorders. Research was facilitated, in largest measure, by the creation of pharmacologically effective multimodal pharmaceutical formulations. Deployment of neurotheranostic agents could revolutionize staging and improve nervous system disease therapeutic outcomes. However, obstacles in formulation design, drug loading and payload delivery still remain. These will certainly be aided by multidisciplinary basic research and clinical teams with pharmacology, nanotechnology, neuroscience and pharmaceutic expertise. When successful the end results will provide “optimal” therapeutic delivery platforms. The current report reviews an extensive body of knowledge of the natural history, epidemiology, pathogenesis and therapeutics of neurologic disease with an eye on how, when and under what circumstances neurotheranostics will soon be used as personalized medicines for a broad range of neurodegenerative, neuroinflammatory and neuroinfectious diseases.",
keywords = "Alzheimer's disease (AD), Blood brain barrier (BBB), Brain-targeted nanoparticles, Magnetic resonance imaging (MRI), Nanomedicine, Neurodegenerative disorders, Neuroimaging, Neurotheranostics, Parkinson's disease (PD), Single photon emission computed tomography (SPECT/CT), Theranostics",
author = "Kevadiya, {Bhavesh D.} and Ottemann, {Brendan M.} and Thomas, {Midhun Ben} and Insiya Mukadam and Saumya Nigam and McMillan, {JoEllyn M} and Santhi Gorantla and Bronich, {Tatiana K} and Edagwa, {Benson J} and Gendelman, {Howard Eliot}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.addr.2018.10.011",
language = "English (US)",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Neurotheranostics as personalized medicines

AU - Kevadiya, Bhavesh D.

AU - Ottemann, Brendan M.

AU - Thomas, Midhun Ben

AU - Mukadam, Insiya

AU - Nigam, Saumya

AU - McMillan, JoEllyn M

AU - Gorantla, Santhi

AU - Bronich, Tatiana K

AU - Edagwa, Benson J

AU - Gendelman, Howard Eliot

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The discipline of neurotheranostics was forged to improve diagnostic and therapeutic clinical outcomes for neurological disorders. Research was facilitated, in largest measure, by the creation of pharmacologically effective multimodal pharmaceutical formulations. Deployment of neurotheranostic agents could revolutionize staging and improve nervous system disease therapeutic outcomes. However, obstacles in formulation design, drug loading and payload delivery still remain. These will certainly be aided by multidisciplinary basic research and clinical teams with pharmacology, nanotechnology, neuroscience and pharmaceutic expertise. When successful the end results will provide “optimal” therapeutic delivery platforms. The current report reviews an extensive body of knowledge of the natural history, epidemiology, pathogenesis and therapeutics of neurologic disease with an eye on how, when and under what circumstances neurotheranostics will soon be used as personalized medicines for a broad range of neurodegenerative, neuroinflammatory and neuroinfectious diseases.

AB - The discipline of neurotheranostics was forged to improve diagnostic and therapeutic clinical outcomes for neurological disorders. Research was facilitated, in largest measure, by the creation of pharmacologically effective multimodal pharmaceutical formulations. Deployment of neurotheranostic agents could revolutionize staging and improve nervous system disease therapeutic outcomes. However, obstacles in formulation design, drug loading and payload delivery still remain. These will certainly be aided by multidisciplinary basic research and clinical teams with pharmacology, nanotechnology, neuroscience and pharmaceutic expertise. When successful the end results will provide “optimal” therapeutic delivery platforms. The current report reviews an extensive body of knowledge of the natural history, epidemiology, pathogenesis and therapeutics of neurologic disease with an eye on how, when and under what circumstances neurotheranostics will soon be used as personalized medicines for a broad range of neurodegenerative, neuroinflammatory and neuroinfectious diseases.

KW - Alzheimer's disease (AD)

KW - Blood brain barrier (BBB)

KW - Brain-targeted nanoparticles

KW - Magnetic resonance imaging (MRI)

KW - Nanomedicine

KW - Neurodegenerative disorders

KW - Neuroimaging

KW - Neurotheranostics

KW - Parkinson's disease (PD)

KW - Single photon emission computed tomography (SPECT/CT)

KW - Theranostics

UR - http://www.scopus.com/inward/record.url?scp=85056173576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056173576&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2018.10.011

DO - 10.1016/j.addr.2018.10.011

M3 - Article

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

ER -